SecBot SecBot
SECBOTREPLAY Home › Report › KROS

KROS · Keros Therapeutics announced a $20 million development milestone…

Keros Therapeutics, Inc. · 8-K filed Jul 30, 2026 at 16:01 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jul 30, 2026 at 16:01 ET

Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial for elritercept. The company expects to distribute 25% of the net cash proceeds from this milestone to stockholders, providing a tangible near-term capital return catalyst.

  • $20 million development milestone payment from Takeda triggered by first patient dosed in Phase 3 ELRiSE MDS trial
  • Phase 3 trial (ELRiSE MDS) is a multicenter, open-label, randomized study comparing elritercept vs epoetin alfa in low-risk MDS
  • Keros expects to distribute 25% of net cash proceeds from this milestone to stockholders
  • Under the global license agreement (effective Jan 16, 2025), Keros received $200M upfront in Feb 2025 and is eligible for up to $1.1B+ in milestones plus tiered royalties

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access